The implications of the microbiome on Coronavirus disease 2019 (COVID-19) prognosis has not been thoroughly studied. In this study we aimed to characterize the lung and blood microbiome and their implication on COVID-19 prognosis through analysis of peripheral blood mononuclear cell (PBMC) samples, lung biopsy samples, and bronchoalveolar lavage fluid (BALF) samples. In all three tissue types, we found panels of microbes differentially abundant between COVID-19 and normal samples correlated to immune dysregulation and upregulation of inflammatory pathways, including key cytokine pathways such as interleukin (IL)-2, 3, 5-10 and 23 signaling pathways and downregulation of anti-inflammatory pathways including IL-4 signaling. In the PBMC samples, six microbes were correlated with worse COVID-19 severity, and one microbe was correlated with improved COVID-19 severity. Collectively, our findings contribute to the understanding of the human microbiome and suggest interplay between our identified microbes and key inflammatory pathways which may be leveraged in the development of immune therapies for treating COVID-19 patients.
【저자키워드】 COVID-19, SARS-CoV-2, Inflammation, coronavirus, Microbiome, Lung microbiota, blood microbiota, 【초록키워드】 Coronavirus disease 2019, therapy, Anti-inflammatory, Prognosis, COVID-19 severity, lung, cytokine, immune, Peripheral blood, Bronchoalveolar lavage fluid, pathway, PBMC, signaling pathway, BALF, Blood, IL-4, COVID-19 prognosis, Signaling, Analysis, microbe, inflammatory pathways, immune dysregulation, mononuclear cell, tissue, upregulation, downregulation, treating COVID-19 patients, implication, contribute, correlated, inflammatory pathway, 【제목키워드】 identification,